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Abstract:  Beryllium  is  a  lightweight  metal  with  unique  qualities  related  to  stiffness, 
corrosion resistance, and conductivity. While there are many useful applications, researchers 
in the 1930s and l940s linked beryllium exposure to a progressive occupational lung disease. 
Acute beryllium disease is a pulmonary irritant response to high exposure levels, whereas 
chronic beryllium disease (CBD) typically results from a hypersensitivity response to lower 
exposure levels. A blood test, the beryllium lymphocyte proliferation test (BeLPT), was an 
important advance in identifying individuals who are sensitized to beryllium (BeS) and thus 
at  risk  for  developing  CBD.  While  there  is  no  true  "gold  standard"  for  BeS,  basic 
epidemiologic  concepts  have  been  used  to  advance  our  understanding  of  the  different 
screening algorithms. 
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1. Background 
Beryllium (Be) is a lightweight metal with valuable physical and chemical properties that include 
stiffness, corrosion resistance, and electrical and thermal conductivity [1]. Since the first commercial 
use in  the 1920s,  it has  been used in a growing number of commercial and defense applications, 
including aircraft and satellite structures, nuclear applications, precision instruments, and high speed 
electronic circuits [2].  
 
1.1. Early Disease Reports 
 
European researchers first linked beryllium exposure to occupational lung disease in the 1930s [3]. 
Beginning in the 1940s, researchers in the United States showed that chronic beryllium disease (CBD) 
was an immunologically mediated granulomatous lung disease that could result from the inhalation of 
airborne beryllium particles [2].  
Although a recent paper argues otherwise [4], most researchers have distinguished between acute 
and  chronic  beryllium  disease.  Acute  beryllium  disease  results  from  an  irritant  response  at  high 
exposure levels, whereas chronic beryllium disease (CBD) typically results from a hypersensitivity 
response  to  lower  exposure  levels.  This  article  provides  an  overview  of  advances  in  identifying 
beryllium sensitization and disease in the United States. 
 
1.2. The Beryllium Registry           
    
To  clarify  the  epidemiology  and  natural  history  of  beryllium  disease,  the  U.S.  Beryllium  Case 
Registry was established in 1952 at the Massachusetts Institute of Technology. It later moved to the 
National Institute for Occupational Safety and Health (NIOSH) and is now closed. Adding a case to the 
Registry required documentation of beryllium exposure plus any three of the four criteria summarized 
below [5,6]: 
(1) lower respiratory symptoms; 
(2) reticulonodular infiltrates on chest x-ray;  
(3) restrictive or obstructive pulmonary impairment, or depressed diffusing capacity;    
 (4) biopsy showing non-caseating granulomas or mononuclear cell interstitial infiltrates.  
Approximately 900 cases were entered into the registry, including 65 cases among family members 
exposed  to  "worker  take  home"  dust  and  residents  exposed  through  off-site  air  pollution. 
Unfortunately, the registry criteria were not sufficiently specific to fully distinguish between chronic 
beryllium disease and sarcoidosis, a clinically similar granulomatous lung disease that is not associated 
with beryllium [7].  
 
1.3. Exposure and Susceptibility 
 
To develop CBD, an individual must be exposed and then develop immunologic sensitization to 
beryllium (BeS) over a period of months or years. The physical form and physicochemical properties Int. J. Environ. Res. Public Health 2010, 7                 
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may play a role in beryllium toxicity [8,9]. In addition to inspired beryllium particles, researchers have 
suggested that skin contact with fine beryllium dust may play a role in sensitization [10].  
In  2004,  NIOSH  estimated  that  up  to  134,000  workers  in  the  United  States  were  exposed  to 
beryllium [11]. The Occupational Safety and Health Administration (OSHA) Permissible Exposure 
Limit for beryllium in air is 2.0 micrograms per cubic meter averaged over an eight-hour work day. 
This exposure limit is widely recognized as failing to protect exposed workers from sensitization and 
chronic beryllium disease [12]. In addition, there are currently no requirements that prevent general 
industry beryllium workers from inadvertently taking beryllium dust home on their clothing. 
Recent cross-sectional studies indicate that the prevalence rates of BeS and CBD among beryllium 
workers lie between 5−21% and 3−21%, respectively [12]. A growing body of evidence indicates that 
genetic susceptibility of the exposed workers also contributes to beryllium disease outcomes [13].  
 
1.4. The BeLPT 
 
CBD case identification was improved by the development and spread of the beryllium lymphocyte 
proliferation  test  (BeLPT)  in  the  early  1980s.  The  BeLPT  can  detect  evidence  of  beryllium 
sensitization in the blood before there is evidence of pulmonary disease. Abnormal BeLPT results 
identify individuals at higher risk for disease and typically lead to further medical evaluation to rule  
out CBD.  
To perform the BeLPT, T-lymphocytes are incubated in three concentrations of beryllium sulfate 
over  two  time  periods  for  a  total  of  six  "exposed"  incubations.  The  beryllium  sulfate  stimulates 
sensitized  T-lymphocytes  to  take  up  tritiated  thymidine.  The  radiation  levels  are  compared  for 
incubations  with  and  without  beryllium  sulfate.  The  relative  radiation  levels  for  the  BeLPT  are 
interpreted as follows: 
(a) normal test result (NL)—0 of 6 incubations with Be are elevated; 
(b) borderline test result (BL)—1 of 6 incubations with Be are elevated; and,  
(c) abnormal test result (AB)—2 or more incubations with Be are elevated.  
 
1.5. Test-Retest Inconsistencies 
 
Deubner et al. [14] explored issues associated with the validity of the BeLPT in an article published 
in  2001.  They  noted  substantial  intra-  and  inter-laboratory  disagreement  among  the  laboratories 
evaluated. Concern about these inconsistencies has led practitioners to require serial testing and various 
combinations of test results to confirm sensitization to beryllium. 
 
2. Introduction 
 
2.1. The Expert Panel 
 
On April 26, 2006, ATSDR convened an expert panel in Ottawa County, Ohio [15]. The seven 
member panel included physicians with beryllium expertise who were associated with environmental Int. J. Environ. Res. Public Health 2010, 7                 
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activism, industry, and universities or government. The panel was asked to provide input to ATSDR on 
various issues related to the BeLPT. When asked about the criteria that provided sufficient BeLPT 
evidence of sensitization for referral and medical evaluation, the various panelists' suggested criteria 
that included: 
(a) one abnormal result,  
(b) one abnormal and one borderline result, and,  
(c) two abnormal results.  
Two  abnormal  results  have  historically  been  used  in  lieu  of  a  "gold  standard"  for  beryllium 
sensitization  in  beryllium  research  [14,16],  though  it  is  not  as  sensitive  as  other  criteria.  Using 
probability modeling, a previous manuscript considered the overall sensitivity, specificity, and positive 
predictive values for true BeS for the three different criteria (above) in common use [17].  
The exposure context is also important when interpreting results for the individual. That is, the 
exposure level alters the expected group prevalence and therefore affects the positive predictive value 
of individual test results.  
 
2.2. Confusing Issues 
 
One thing evident from the panel's deliberations was a lack of consensus on the "best" criteria for 
BeS, or even on what testing characteristics were the most important. For example, one abnormal is 
the  most  sensitive  criterion,  but  two  abnormals  provide  more  specificity.  The  overall  sensitivity, 
specificity, and predictive values of the various criteria and associated algorithms for BeS were largely 
unknown. In this review, we use these terms generally to mean:  
Sensitivity—the proportion of persons with BeS that test abnormal; 
Specificity—the proportion of persons without BeS who test normal; 
Positive predictive value (PPV) – the proportion of persons testing abnormal who are truly BeS. 
Estimates  of  these  parameters  are  needed  to  support  informed  decisions  regarding  referral  for 
medical evaluation. Further, the following question remained to be addressed: Is there a background 
level of BeS in the general population? 
 
3. Probability Modeling 
 
As noted, there is no true gold standard for BeS. Given that the BeLPT is only moderately sensitive 
but highly specific for BeS, Stange et al. [16] found an ingenious way to circumvent this problem. It 
follows from these epidemiologic characteristics that usually: 
(a) if a true positive occurs, additional testing will confirm it; and, 
(b) if a false positive occurs, additional testing will not confirm it.  
This allowed Stange to propose a working gold standard based on serial testing to confirm (or not) 
any  abnormal  result.  That  is,  if  a  total  of  two  abnormals  were  documented,  the  individual  was 
identified as BeS; if not, the first abnormal was considered a false positive. This provided the data 
necessary to evaluate the sensitivity and specificity of the single BeLPT test, the building blocks for 
modeling the performance of testing algorithms and associated criteria for BeS. Int. J. Environ. Res. Public Health 2010, 7                 
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3.1. Building a Foundation 
 
Stange et al. [16] reported that a single BeLPT's sensitivity was 0.683 and the specificity was 0.969. 
Middleton et al. [18] adjusted Stange's parameters to consider borderline test results and found that, for 
persons  truly  sensitized  to  beryllium,  the  single  test  outcome  probabilities  are:  PAB  =  0.5970;  
PNL = 0.2770; and, PBL = 0.1260. Similar calculations can be done for persons not truly sensitized to 
beryllium; in this group, the single test outcome probabilities are: PAB = 0.0109; PNL = 0.9733; and  
PBL = 0.0158. 
 
3.2. Probability Modeling 
 
Since we know that the probability of one coin toss resulting in one head (or one tail) is 1/2, we 
calculate the probability of getting a head and then a tail as follows: p = 1/2 * 1/2 = ¼; that is, p = 0.25. 
The  same  logic  can  quantify  the  modeling  specified  in  various  testing  algorithms.  For  example, 
consider Figure 1 and Table 1. 
Figure 1. One abnormal BeLPT provides sufficient evidence for beryllium sensitization. 
.   
Table 1. Likelihood of Meeting BeS Criteria (One Abnormal BeLPT) for Individuals Truly 
Sensitized 
1. 
Results  that Meet  Criteria 
2   Test 1   Test 2   Test 3 
Outcome Probability 
p = p1 * p2 * p3 
Combination 1  abnormal  ---  ---  0.5970 
Combination 2  borderline  abnormal  ---  0.0752 
Combination 3  borderline  borderline  abnormal  0.0095 
Overall likelihood of meeting the criteria of one abnormal   0.6817 
1  The single test probabilities for persons truly sensitized [17] are pAB = 0.5970, pBL= 0.1260, and pNL= 0.2770. 
2 Test Results that Meet Criteria" are groups of 1, 2, or 3 test results that combine to meet the sensitization 
criteria specified (in this case, one abnormal BeLPT). Int. J. Environ. Res. Public Health 2010, 7                 
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Note that ―Combination 1‖ is nothing more than an abnormal result on ―Test 1‖, which requires no 
additional testing. The probability of this outcome is simply the single test probability that a truly 
sensitized person will have an abnormal result on any particular test (0.5970). Using the algorithm in 
Figure 1, note that borderline test results are simply repeated. Combination 2 requires a borderline  
(pBL = 0.1260) followed by an abnormal (pAB = 0.5970); the probability of this combination is the 
product of these probabilities, or p = 0.1260 * 0.5970 = 0.0752. Combination 3 requires a borderline, 
then a second borderline, and finally an abnormal; the product of these three probabilities is 0.0095. 
Adding these three probabilities yields 0.6817, the probability of meeting the criteria if the individual is 
truly BeS. This is also the algorithm's overall ―sensitivity‖. 
Figure 2. One abnormal and one borderline provide sufficient evidence for beryllium sensitization. 
 
Figures 3. Two abnormal BeLPTs provide sufficient evidence for beryllium sensitization. 
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The  individual  tables  for  Figures  2  and  3  are  not  presented  in  this  review,  but  are  published 
elsewhere [17]. The overall characteristics for each algorithm/criteria are shown in Table 2.  
 
Table 2. Overall Sensitivity, Specificity, and Positive Predictive Value, by the Specified 
Sensitization Criteria 
1. 
Sensitization Criteria  Sensitivity  Specificity  PPV at4% BeS 
2 
1 AB  0.682  0.9889  0.719 
1 AB + 1 BL  0.657  0.9992  0.972 
2 AB  0.612  0.9998  0.992 
1  Positive predictive value (PPV) also varies by prevalence; the PPV's shown are for a population with 
4% prevalence of BeS. 
2  The specified sensitization criteria imply the groups of results combinations that are evaluated together. 
The nominal criteria is actually the minimum. 
 
3.3. The National Research Council (NRC) 
 
Government agencies have differed greatly in their approach to protecting workers from the health 
effects associated with exposure to beryllium. The U.S. Department of Energy has a comprehensive 
program for hygiene, housekeeping, personal protective equipment, and testing for current and former 
workers. Historically, Department of Defense policy statements have discouraged use of the BeLPT for 
the screening or surveillance of exposed workers [15]. However, more recently the U.S. Air Force 
asked a committee of the National Research Council (NRC) to conduct an independent review of the 
scientific literature on beryllium and to make recommendations for exposure- and disease-management 
[18]. Committee members had expertise in pulmonary medicine, occupational medicine, epidemiology, 
industrial hygiene, toxicology, pathology, biostatistics, and risk assessment.  
Among  the  topics  covered  in  the  2008  NRC  report  was  the  role  of  the  BeLPT  in  worker 
surveillance. The committee concluded that: 
"The  BeLPT  is  integral  to  any  screening  program.  No  alternative  tests  have  been 
adequately validated to be put into practice outside research settings." 
The algorithm recommended to the Air Force was taken from the article by Middleton et al. [15]. 
This algorithm is based on the criteria of "one abnormal plus one borderline." Citing Stange et al. [16] 
and Middleton et al. [15,17], the NRC committee also advised consideration of the prevalence of BeS 
in the population being tested.  
Finally, the NRC noted that current practice is not always strictly limited to a specific algorithm, but 
considers results collected at various times over long time periods. For example, one abnormal BeLPT 
result  that  is  followed  first  by  two  normals  and  then  later  by  another  abnormal,  is  considered 
equivalent to two sequential abnormals and the individual is referred for evaluation. The committee 
acknowledged  some  uncertainty,  but  suggested  that  the  current  approach  continue  until  data  is 
available to clarify the impact of such practices.  
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4. Validation 
 
The question of interest is: "How well does it predict what will happen when a different group of 
individuals is tested?". To date, the sensitivity and positive predictive value estimates are based on the 
exposed workers studied by Stange et al. [16] and have not been compared to the screening experience 
in  other  populations.  However,  some  simple  checks  on  the  specificity  of  the  BeLPT  are  readily 
available and are described below.  
 
4.1. DOE Pre-hires at Rocky Flats 
 
In addition to the exposed workers, Stange et al. [16] also studied 291 new hires who had not yet 
been occupationally exposed to beryllium. While three of the 291 (1%) had an abnormal BeLPT result, 
none of the three individuals with abnormal results was confirmed by a second abnormal. While this 
doesn’t tell us anything about the sensitivity of the BeLPT, it does suggest that confirmed results 
provide specific evidence for beryllium sensitization. That is, false positives do not seem to be a big 
problem when confirmation is required by the criteria.   
 
4.2. Manatee County, FL 
 
ATSDR  tested  114  residents  of  Manatee  County  who  lived  near  a  machine  shop  that  used 
beryllium; none were workers or household contacts of workers. There were one abnormal (0.88%) and 
two borderline (1.75%) results during the first round of testing. Given that the machine shop had no 
stack emissions, this population was probably unexposed and unsensitized. For such a population, the 
estimates developed in Middleton et al. [17] predict 1.09% abnormal and 1.58% borderline results. As 
also  predicted  by  the  model,  none  of  these  abnormal  results  were  confirmed  as  BeS  during  
follow-up testing.  
 
4.3. Japan 
 
Yoshida et al. tested 159 new hires in Japan. Of these unexposed workers, two (1.26%) had an 
abnormal result, consistent with a predicted rate of 1.09%. No information about follow-up testing to 
confirm  sensitization  was  provided.  Insofar  as  we  can  tell,  these results  are consistent  with  those 
among unexposed persons in the United States.  
 
4.4. Ottawa County, OH 
 
While  the remaining  beryllium  producer in  the United States has reported a low prevalence of 
beryllium sensitization among new hires (~1%) [19], the consistent lack of confirmed sensitization 
among other groups seems more likely to be representative of the general population. Through local 
hiring and hiring relatives of current workers, some of the new hires at this facility may have had prior Int. J. Environ. Res. Public Health 2010, 7                 
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exposure  to  beryllium.  Further,  confirmation  testing  at  this  facility  is  generally  conducted  after 
beginning work at the plant.  
 
5. Conclusions  
 
5.1. Modeling vs. Measurement 
 
As suggested by the NRC committee, testing does not always follow a strictly defined protocol. This 
clearly  has  implications  for  predictions  generated  by  the  models,  but  the  specifics  are  not  well 
understood.  One  useful  approach  would  be  to  measure  the  actual  predictive  value  of  various 
combinations of results in a specific exposed population for identifying persons eventually determined 
to be sensitized to beryllium. The relationship between various combinations of BeLPT results and 
eventually  developing  CBD,  if  one  exists,  also  has  yet  to  be  clarified.  That  is,  within  the  same 
algorithm, are specific combinations confirming sensitization more predictive of CBD than others? 
 
5.2. Not Truly Sensitized 
 
The test results for persons not exposed (and therefore not truly sensitized) appear to be consistent 
with the models' predictions. Screening BeLPT results among unexposed persons are rarely abnormal 
(1.09%), rarely borderline (1.58%), and in most populations, not confirmed by followup testing when 
they do occur. That is, the sensitization criteria that require confirmation seem to be very specific  
for BeS. 
 
5.3. Truly Sensitized 
 
Similar  evaluations  need  to  be  done  with  persons  who  are  truly  sensitized  to  validate  that  the 
algorithms function as predicted in identifying persons truly sensitized to beryllium. Further, grouping 
outcomes by those that meet the minimum criteria results (e.g., 1 AB + 1 BL + 1 NL) is not entirely 
satisfactory, since the positive predictive values calculated apply to the algorithm outcomes as a whole 
rather than to any specific outcome. Future publications by the authors and other collaborators will 
attempt to clarify these issues. 
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